Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Atrium acquisitions boost revenues

This article was originally published in The Tan Sheet

Executive Summary

Canadian health and nutrition products manufacturer and marketer Atrium Innovations says acquisitions and organic sale growth drove a 15.5 percent increase in net revenues to $70.6 million in its 2009 first quarter. Atrium in January purchased probiotic firm Nutri-Health Supplements of Cottonwood, Ariz., and added German enzyme manufacturer Enzym-Arzneimittel-Berlin to its operations in late 2008 (1"The Tan Sheet" Jan. 12, 2009, In Brief). The Quebec City-based firm said May 12 that it anticipates increasing U.S. sales of Wobenzym N enzyme support formula, which is approved for sale at Whole Foods. Net earnings during the January-March period from continuing operations were essentially flat, inching up to $10.6 million from $10.5 million

You may also be interested in...

Atrium buys probiotic firm

Atrium Innovations adds Multi-Probiotic, a blend of 16 probiotic strains that sold $27 million in 2008, to its portfolio with its acquisition of Nutri-Health Supplements in Cottonwood, Ariz. Quebec City-based Atrium Jan. 5 says it also gained Sedona Labs, Meta Foods and Sedona Labs Pro in the $23.9 million cash deal. Atrium also will make two earn-out payments based on NHS product sales in 2009 and 2010

Celltrion Healthcare Gears Up For Infliximab SC Launch

As Celltrion Healthcare prepares to roll out Remsima SC, its subcutaneous infliximab, in Europe – starting in the UK and Germany – Celltrion Healthcare’s UK commercial head, Matthew Eddleston, speaks to Generics Bulletin about how the innovative biosimilar will be positioned in the market.

Congress Tackles Overpriced ‘Surprise’ Medical Bills, Taking Several Different Tacks

A trio of legislative proposals to lower high-cost “surprise” medical bills that limit what physicians and hospitals, labs, and imaging facilities can charge patients, emerged this winter from three different US congressional committees with health care jurisdiction. Check out our detailed chart that sorts out some of the provisions of the bills of interest to device and diagnostics firms.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts